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LETTERS
Mycobacterium
tuberculosis
Complex Drug
Resistance in Italy
To the Editor: The reemergence
of tuberculosis (TB) as a global health
problem over the past 2 decades,
accompanied by increased drug resist-
ance, which represents a serious prob-
lem both in terms of TB control and
clinical management (1), prompted
Western European countries to devel-
op comprehensive national surveil-
lance systems to monitor trends in TB
drug resistance. Moreover, the World
Health Organization (WHO) and the
International Union Against
Tuberculosis and Lung Disease
(IUATLD) launched the Global
Project on Anti-Tuberculosis Drug
Resistance Surveillance to measure
the prevalence of drug resistance by
using standardized methods and
assess its correlation with indicators
of TB control (2,3). Since comprehen-
sive data on resistance to firstline
drugs were not available in Italy, a
network of 20 regional laboratories
was established to participate in this
project. The Department of
Bacteriology and Medical Mycology
of Istituto Superiore di Sanità in
Rome and the Mycobacteriology Unit
of Istituto Villa Marelli in Milan
(appointed respectively as
Supranational Reference Laboratory
and National Reference Laboratory)
supervised and controlled the network
of regional laboratories. The combi-
nation of reference laboratories in the
network and associated clinical units,
which covered 30% of definite cases
reported each year (4), was known as
SMIRA (Italian Multicentre Study on
Resistance to Anti-Tuberculosis
Drugs). The WHO/IUATLD coordi-
nating center in Ottawa, Canada, pro-
vided a batch of 20 Mycobacterium
tuberculosis  strains to set up profi-
ciency testing to check drug suscepti-
bility procedures in all SMIRA labo-
ratories (5). We summarize the nature
and extent of TB drug resistance in
Italy between 1998 and 2001. 
Isolates from all consecutive, defi-
nite cases diagnosed in TB units dur-
ing 1998 through 2001 were included.
When a patient’s previous treatment
status was unknown or dubious, the
case was excluded. Resistant cases
from patients with and without histo-
ry of previous treatment were strati-
fied by the following categories: any
resistance, monoresistance, resistance
to both isoniazid and rifampicin
(known as rifampin in the United
States), or resistance to three or more
drugs. Confidence intervals were also
calculated. Participating laboratories
were allowed to use the WHO-recom-
mended drug susceptibility method
with which they were most familiar:
absolute concentration method, resist-
ance ratio method, proportion method
and its variants, or BACTEC 460
radiometric method (Becton Dick-
inson, Towson, MD) (6,7). Among the
laboratories reporting results by the
proportion method, the majority used
Löwenstein-Jensen medium while
others used liquid nonradiometric
media (8). Each of the 20 M. tubercu-
losis strains was tested against firstline
drugs by the Italian Reference
Laboratories in Rome and Milan and
classified as resistant or susceptible.
Results were compared to the standard
criterion, represented by the judicial
results of the WHO/IUATLD Global
Network of Supranational Labor-
atories (9). Each network laboratory
was validated for each firstline drug
when no more than two results were
different from the standard criterion. 
The prevalence of drug resistance
detected during the period 1998–2001
is summarized in the Table. Among
previously untreated cases, the preva-
lence of resistance to isoniazid,
rifampicin, ethambutol, and strepto-
mycin was 3.5%, 0.8%, 0.5%, and
4.3%, respectively, while prevalence
of multidrug resistance (resistance to
at least isoniazid and rifampicin) and
polyresistance (resistance to two or
more drugs, but not both isoniazid and
rifampicin) was 1.1% and 2.4%,
respectively. No difference was found
by stratifying prevalence data by age,
sex, or HIV status. In isolates from
patients with previous treatment, drug
resistance was found to be almost four
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Table. Pattern of drug resistance among strains from tuberculosis patients with and without a history of treatment, Italy 1998–2001
a 
No history of previous treatment  History of previous treatment 
Tested MTB strains   No.  %  95% CI  No.  %  95% CI 
Total tested   2,117  100  –  322  100  – 
Fully sensitive   1,847  87.2  85.8 to 88.6  155  48.1  42.7 to 53.6 
Any drug   270  12.7  11.4 to 14.2  167  51.8  46.4 to 57.3 
INH   75  3.5  2.8 to 4.4  17  5.3  3.2 to 8.2 
RMP  17  0.8  0.5 to 1.3  14  4.3  2.5 to 7.0 
EMB   10  0.5  0.2 to 0.8  1  0.3  0.02 to 1.5 
SM  93  4.3  3.6 to 5.3  14  4.3  2.5 to 7.0 
Resistant to both INH and RMP   8  0.40  0.8 to 0.7  24  7.5  4.9 to 10.7 
Resistant to INH, RMP, EMB   2  0.10  0.01 to 0.3  19  6.0  3.7 to 8.9 
Resistant to INH, RMP, SM   6  0.30  0.1 to 0.6  23  7.1  4.7 to 10.4 
Resistant to INH, RMP, EMB, SM   7  0.30  0.1 to 0.6  32  9.9  7.0 to 13.5 
aMTB, Mycobacterium tuberculosis complex; CI, confidence interval; INH, isoniazid; RMP, rifampicin; EMB, ethambutol; SM, streptomycin. LETTERS
times higher than in those from
patients with no history of treatment.
However, the prevalence of monore-
sistant strains was low (5.3%, 4.3%,
0.3%, and 4.3% for isoniazid,
rifampicin, ethambutol, and strepto-
mycin, respectively) compared with
the prevalence of multidrug-resistant
strains whose rate reached a peak of
30.4%. 
Drug-resistant TB in countries
with good national control programs,
such as in Western Europe, is not
commonly a major health problem,
although increasing immigration
prompts public health authorities to
maintain vigilant surveillance sys-
tems. The results of our study indi-
cate that throughout Italy, prevalence
of resistance to firstline drugs and
multidrug resistance among isolates
from new cases was consistently low
over the 4-year survey period.
Prevalence of multidrug resistance
among isolates from previously treat-
ed patients was high, although a
downward trend could be demon-
strated during the last 2 years. Since
almost 2 out of 10 isolates resistant to
rifampicin were multidrug resistant,
using rapid molecular methods to
identify rifampicin resistance in ques-
tionable cases appears cost-effective
to facilitate early detection and con-
trol of multidrug-resistant TB (10).
Resistance to isoniazid is associated
with immigration from countries
where isoniazid was used extensively
in the past. This information is a use-
ful tool for clinicians, as isoniazid
resistance may be suspected early in
the disease and properly treated.
Finally, the finding of substantial
multidrug resistance among isolates
from previously treated patients,
combined with the evidence that
immigrants from areas where isoni-
azid resistance is endemic contribute
substantially to the number of new
TB cases in Italy every year, strongly
suggests that public health action is
needed to improve treatment out-
comes. 
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Mollaret-like Cells
in Patients with
West Nile Virus
Infection
To the Editor: We have read with
interest many of the articles concern-
ing West Nile virus (WNV) published
in the July 2003 issue of Emerging
Infectious Diseases. Last summer
Ohio was one of the leading states
with WNV infection in humans.
Consequently, requests for tests for
this pathogen have increased.
Unfortunately, the turnaround time
for testing these specimens may be
delayed because of shipping difficul-
ties, the limited number of laborato-
ries that can perform these assays,
and an increase in requests at testing
facilities. 
Cytologic examination of cere-
brospinal fluid (CSF) from patients
with WNV has not been studied.
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